Drugs / Gestrinone
Gestrinone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05570786 | Feb 2023 → May 2025 | endometriosis | Science Valley Research Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06543550 | Jul 2024 → Sep 2025 overdue | endometriosis | Bio Meds Pharmaceutica Ltda | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gestrinone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06543550 ↗ |
| Known as | A 46 745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1868702 ↗ |
| Known as | Dimetriose | ChEMBL registry synonym — accepted as the source's own label CHEMBL1868702 ↗ |
| Known as | Gestrinona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1868702 ↗ |
| Known as | R 2323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1868702 ↗ |
| Known as | RU 2323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1868702 ↗ |
| Action | Inhibit | “Gestrinone is a synthetic derivative of 19-nortestosterone with anti-estrogen, anti-progestin, androgenic, and weak estrogen-like action.” NCT05570786 ↗ |
| Modality | Small molecule | “Gestrinone is a synthetic derivative of 19-nortestosterone with anti-estrogen, anti-progestin, androgenic, and weak estrogen-like action.” NCT05570786 ↗ |
| Route | Other | “subdermal implantation of the gestrinone (85 mg)” NCT05570786 ↗ |